Treatment of uncomplicated falciparum malaria with artemisinin-based therapy might cause asymptomatic liver enzyme abnormalities in the first days of treatment.
The findings of this study call for a need to review the Sudan malaria treatment policy.
The IPCA products contained the same drugs in the same amount as on their package label and were identical to the reference product.
The reduced ACT availability and irregular pattern of supply were due to cumbersome bureaucratic processes and delays both within the country and the main donor, the Global Fund to Fight AIDS, Tuberculosis and Malaria.
A therapeutic efficacy study was conducted using artemetherlumefantrine + primaquine against P. vivax to evaluate a treatment alternative for chloroquine.
Both formulations of artemisinin-based combination therapy were effective over time and no severe adverse events related to the treatment were reported during the studies.
A cluster quasi-experimental study. The authors developed strategies to address challenges encountered by healthcare providers during clinical management of malaria. The primary outcome was patient knowledge on prescribed malaria drug treatment.
ASAQ was comparatively well-tolerated. Safety information is important, and must be collected and analysed in a standardized way.
In this pharmacovigilance study, the exposed group (pregnant women with malaria given artemether-lumefantrine), and a matched non-exposed group (pregnant women without malaria and no exposure to artemether-lumefantrine) were followed until delivery.
We conducted a randomized trial comparing artemether-lumefantrine, artesunate plus amodiaquine (AS+AQ) and artesunate plus sulfadoxine-pyrimethamine (AS+SP) in patients 6 months of age and older with uncomplicated malaria in Mali from July 2005 to July 2007.